Stapokibart injection for moderate to severe bullous pemphigoid
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new injection called Stapokibart to see if it can help people with moderate to severe bullous pemphigoid, a skin condition that causes painful blisters. The treatment aims to reduce blistering and itching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 90 years old.
- You must have a confirmed diagnosis of bullous pemphigoid.
- Your skin condition must be moderate to severe, as measured by a doctor using a special score.
- You must have significant itching, rated at least 4 out of 10 on average.
- You must be generally well enough to perform daily activities (score of 50% or higher on a standard health scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
This study looks at how well an allergy injection called Stapokibart works for people with seasonal allergic rhinitis (hay fever). If you qualify, you'll receive the treatment as part of your normal care, and the study team will track your results.
This study is a follow-up for children who have already completed the first 18 weeks of treatment with the study medicine for atopic dermatitis (also called eczema). It tests whether the medicine continues to be safe and effective over a longer time.
This trial tests a new biologic medicine (injection) to see if it can better control seasonal allergy symptoms in teens who haven't had good relief from standard treatments like nasal sprays.
This study tests an injectable medication called Stapokibart for teenagers with seasonal allergies (hay fever). It aims to see if the drug can reduce allergy symptoms like sneezing, runny nose, and itchy eyes.
Hear when a new Bullous Pemphigoid (BP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.